Forward P/S Multiple: Axonics (AXNX)
Axonics, Inc. is recognized as a leader in pelvic dysfunction therapy due to its innovative mini-implants. The forward P/S ratio on this GURU.Markets chart reflects revenue expectations, with the level currently sitting around 2.70. Business growth is driven by clinic partnerships and M&A transactions, while stability is guaranteed by the neutral geopolitical status of the biomedical sector.
Summary analytical data breakdowns for Axonics, Inc (AXNX)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
- financial results and valuation multiples details:
AXNX - Company Net Income|Expected Profit Axonics, Inc.|AXNX - Market Cap to Net Income Ratio|Projected Price to Earnings Axonics Modulation Technologies|AXNX - PEG Multiple|EV/EBITDA Multiple Axonics, Inc|AXNX - Operating income before deduction of amortization|Earnings per share for the last twelve months Axonics|AXNX - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months axonics.com|AXNX - Net earnings per share growth this year|Earnings growth forecast for next year Axonics, Inc.
- sales and revenue indicators:
Fundamental company analysis:AXNX (Axonics)
Forward P/S measures market capitalization relative to projected revenue, allowing for an assessment of the premium paid for expected business scaling. By analyzing the forward P/S of the business, an investor determines the valuation sustainability of Axonics, Inc. (AXNX), where strong pricing power in the neuromodulation niche and synergy with Boston Scientific justify a premium multiple through the expansion of global distribution channels.
Who Axonics, Inc. competes with
Price-to-Projected Revenue Ratio Boston Scientific Corporation BSX|EW - Forward Price-to-Revenue Multiple|ResMed Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Inc.|ZBH: Forward P/S Multiple|Market Cap to Projected Revenue COO|ALGN (Align Technology) - Forward P/S Multiple|Globus Medical Inc (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Corp ATEC|Forward P/S Multiple AORT (Artivion, Inc.)|Forward P/S Multiple enovis.com ENOV|IART - Price-to-Projected Revenue Ratio|ESTA: Price-to-Projected Revenue Ratio|BBNX (Beta Bionics Corp) - Forward Price-to-Revenue Multiple|IRADIMED Inc. - Forward Price to Sales|EMBC (Embecta Corp.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tandemdiabetes.com TNDM|Price-to-Projected Revenue Ratio Axogen (AXGN)|SI-BONE Inc (SIBN) - Projected Price to Revenue|Orthofix International - Forward Price-to-Revenue Multiple|Forward P/S Multiple Bioventus Global BVS|OrthoPediatrics Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio treace.com TMCI|Strata Critical Medical (SRTA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CARL (Carlsmed, Inc.)|Price-to-Projected Revenue Ratio RxSight Corp|Forward Price-to-Revenue Multiple ClearPoint (CLPT)|Forward P/S Multiple STXS|STIM - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Sight Sciences SGHT|OBIO: Market Cap to Projected Revenue|ANIK: Forward Price-to-Revenue Multiple|InspireMD Inc. - Price to Expected Revenue Ratio|ZJYL: Forward P/S Multiple|Vivani Medical (VANI) - Forward P/S Multiple|Forward Price-to-Revenue Multiple XTNT|Market Cap to Projected Revenue NMTC (NeuroOne)|Price-to-Projected Revenue Ratio Modular Medical (MODD)|MYO - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Envoy Medical, Inc. COCH|VVOS: Market Cap to Projected Revenue|enVVeno Medical Corp. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Sintx Technologies SINT|TNON: Forward P/S Multiple|Forward Price-to-Revenue Multiple Lifeward Ltd.|Price-to-Projected Revenue Ratio Autonomix Medical Inc.|invobioscience.com (IVF) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple BBLG (Bone Biologics Corp)|BIOL (BIOLASE Inc.) - Forward Price to Sales|Forward P/S Multiple DYNT (Dynatronics)|Market Cap to Expected Sales Ratio Paragon 28 Inc. (FNA)|INVO - Price-to-Projected Revenue Ratio
